.Attributes Medicine, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- drug conjugate (ADC) tisotumab vedotin led to strengthened progression-free and also total survival, triggering FDA approval and a new procedure choice for patients.